Literature DB >> 8250877

Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome.

S Tsubuki1, H Kawasaki, Y Saito, N Miyashita, M Inomata, S Kawashima.   

Abstract

A tripeptide aldehyde protease inhibitor, benzyloxycarbonyl(Z)-Leu-Leu-leucinal (ZLLLa1), initiates neurite outgrowth in PC12 cells at an optimal concentration of 30nM. This result suggests the existence of a protease which regulates neurite formation in PC12 cells. We report here an attempt to identify this target protease in bovine brain using Z-Leu-Leu-Leu-4-methylcoumaryl-7-amide (ZLLL-MCA), in which the aldehyde moiety of ZLLLa1 was changed to 4-methylcoumaryl-7-amide to serve as a substrate for the protease. As a result, we have purified a proteasome with a molecular weight of about 660 kDa as a ZLLL-MCA degrading protease. The activity of the proteasome was inhibited efficiently by ZLLLa1, and was different from known catalytic activities of proteasome in some aspects, suggesting it to be a novel one. Thus, the proteasome may be involved in the regulation of neurite formation in PC12 cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250877     DOI: 10.1006/bbrc.1993.2378

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

Review 1.  Ubiquitin-mediated proteolysis in learning and memory.

Authors:  D G Chain; J H Schwartz; A N Hegde
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

2.  Proteasome activity correlates with male BMI and contributes to the differentiation of adipocyte in hADSC.

Authors:  Kozue Sakamoto; Youichi Sato; Masako Sei; Ashraf A Ewis; Yutaka Nakahori
Journal:  Endocrine       Date:  2010-01-05       Impact factor: 3.633

Review 3.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

4.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

5.  The lipidated connexin mimetic peptide SRPTEKT-Hdc is a potent inhibitor of Cx43 channels with specificity for the pS368 phospho-isoform.

Authors:  Maura L Cotter; Scott Boitano; Paul D Lampe; Joell L Solan; Josef Vagner; Jose F Ek-Vitorin; Janis M Burt
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

6.  Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Authors:  C Norez; C Vandebrouck; J Bertrand; S Noel; E Durieu; N Oumata; H Galons; F Antigny; A Chatelier; P Bois; L Meijer; F Becq
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

7.  Apoptosis induction resulting from proteasome inhibition.

Authors:  K Shinohara; M Tomioka; H Nakano; S Toné; H Ito; S Kawashima
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

8.  The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.

Authors:  Sabine Eva Dudek; Christina Luig; Eva-Katharina Pauli; Ulrich Schubert; Stephan Ludwig
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

9.  Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons.

Authors:  J H Qiu; A Asai; S Chi; N Saito; H Hamada; T Kirino
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

10.  Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Authors:  Aaron T Wecksler; Sung Hee Hwang; Hiromi I Wettersten; Jennifer E Gilda; Amy Patton; Leonardo J Leon; Kermit L Carraway; Aldrin V Gomes; Keith Baar; Robert H Weiss; Bruce D Hammock
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.